Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICI + Axitinib in Advanced Collecting Duct Carcinoma
NCT06211114Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in collecting duct carcinoma (CDC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective Response Rate up to 2 years. Started Feb 2024; status: recruiting.
02
Conditions
collecting duct carcinoma (CDC)
Beyond the preview
Go deeper on NCT06211114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211114.